Phase I for Acorda's new mechanism of action in heart failure justifies more studies
This article was originally published in Scrip
Executive Summary
Phase I data are sufficient to justify another human clinical trial in the treatment of heart failure with Acorda Therapeutics' glial growth factor 2 (GGF2), which offers a new mechanism of action that may improve heart function through direct repair of cardiac muscle.